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Background: Regulatory T cells (Treg) in allografts are important for the prevention of graft-versus-host disease
(GVHD) post-transplantation. The aim of this study was to compare the contents of Tregs and effector T cells in
granulocyte colony-stimulating factor (G-CSF)-primed bone marrow grafts (G-BM) and peripheral blood grafts (G-PB).
Method: G-BM and G-PB were obtained from 20 allogeneic donors. T-cell subgroups, including conventional T cells
and different types of Treg cells, as well as the percentage of Ki67 expression on CD4+CD25highFoxp3+ Treg cells, were
analyzed using flow cytometry. The levels of interferon-γ (IFN-γ) and interleukin-17 (IL-17) secreted by T cells stimulated
with PMA and ionomycin were also determined by flow cytometry.
Results: The percentage of CD4+CD25highCD127-/dimCD62L+ Treg cells was significantly higher in the G-BM group, with
higher proportions of CD45RA+ naïve Treg cells and higher expression of CD69 on Treg cells in G-BM (P < 0.05).
The percentage of Ki67 expression in CD4+CD25highFoxp3+ Treg cells in G-BM was significantly higher than that
on G-PB. The suppressive functions of Treg cells in inhibiting T-cell activation were comparable between G-BM
and G-PB. The proportions of CD4+CD25−CD69+ Treg subsets as well as Th1 cells in G-BM were also significantly
higher than those in G-PB (P < 0.001). The proportions of conventional T cells and Th17 effector cells were comparable
in G-BM compared with those in G-PB. Thus, the ratio of conventional T cells and CD4+CD25highCD127-/dim regulatory
T cells were lower in G-BM than that in G-PB (P = 0.014).
Conclusion: In addition to the much higher T-cell counts in G-PB grafts that may contribute to more severe GVHD, the
higher frequency of Treg cells and lower ratio of conventional T cells to Treg cells in G-BM compared with G-PB grafts
might reduce GVHD post-transplantation in G-BM compared with G-PB transplantation.
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Allogeneic hematopoietic stem cell transplantation (allo-
HSCT) is the only curative method available for malignant
hematologic diseases. However, its broad application is
limited by the high incidence of graft-versus-host disease
(GVHD). The current allo-HSCT procedures consist* Correspondence: huangxiaojun@bjmu.edu.cn
†Equal contributors
1Peking University People’s Hospital and Peking University Institute of
Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell
Transplantation, No. 11 Xizhimen South Street, Beijing 100044, China
2Peking-Tsinghua Center for Life Sciences, Beijing 100871, China
© 2015 Zhao et al.; licensee BioMed Central. T
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.mostly of bone marrow (BM) cells or granulocyte-colony
stimulating factor (G-CSF)-primed peripheral blood stem
cells (G-PB) or G-CSF-primed bone marrow (G-BM). Al-
though both G-BM and G-PB contain large numbers of
mature donor T cells that could cause GVHD [1], clinical
data have demonstrated that patients undergoing G-PB
transplantation were more likely to acquire severe acute
GVHD refractory to prednisone and chronic GVHD
(cGVHD) with a prolonged requirement for immunosup-
pression therapy to control symptoms compared to G-BMhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Donor characteristics
Characteristics Total (n = 20)
Median age at transplantation, years old (range) 29 (18–54)
Male sex, no. (%) 11 (55%)
Percentage of each T cell subset in CD4+ T cells before G-CSF in the
peripheral blood (mean ± SE)
CD4+CD25highCD127-/low regulatory T cells 3.88 ± 0.48
CD4+CD25highCD62L+ regulatory T cells 3.05 ± 0.52
CD4+CD25−CD69+ regulatory T cells 0.15 ± 0.05
CD4+CD25highCD127+ conventional T cells 71.93 ± 1.90
Th1 cells 39.84 ± 5.02
Th17 cells 3.14 ± 0.39
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remains undefined.
CD4+CD25highCD127-/low regulatory T cells (Treg cells)
have been demonstrated to have immunosuppressive abil-
ity and to be key players in the regulation of immune
responses [3]. Rezvanietal et al. determined that increased
frequencies of CD4+Foxp3+ Treg cells in the peripheral
blood of the donor negatively correlated with the inci-
dence of GVHD in the graft recipient [4]. Subsequent
studies have confirmed this correlation in the recipients
of HLA-identical sibling and unrelated donor stem cell
grafts [5,6], indicating that infused donor Treg cells in
graft contents appear to lessen the severity of GVHD. In
addition, donor immunoregulatory T cells, including
CD4+CD25highCD62L+ regulatory T cells and CD4+
CD25−CD69+ T cells, also contribute to decreased
acute GVHD post-transplantation [7-9]. The CD4+
CD25highCD62L+ T regulatory cell subset has optimal
suppressive and proliferative potential. The CD62L+ cell
subset is a more potent suppressor than the CD62L−
population or unfractionated CD4+CD25+ Treg cells [10];
therefore, only the CD62L+ subpopulation of CD4+CD25+
regulatory T cells protects from lethal acute GVHD [11].
Furthermore, CD69 is generally regarded as an activating
marker, but recent studies have shown that CD69 is an
immunoregulatory molecule induced following activation
[12]. An additional report demonstrated that CD4+CD25−
CD69+ T cells act as a new subset of regulatory CD4+ T
cells characterized by a lack of Foxp3 expression and IL-
10 secretion but with a high expression of CD122 and
membrane-bound TGF-beta1 [13].
Previous work has demonstrated that the in vivo appli-
cation of G-CSF would decrease the number of Treg
cells in the bone marrow and increase the number of
Treg cells in the peripheral blood [14-17]. In addition,
our previous reports have demonstrated that differences
existed in the immunological status between G-BM and
G-PB [14,15,18,19]. However, until now, the Treg con-
tents and function of G-BM and G-PB have not been
comparatively analyzed. The aim of this study was to
explore the contents of regulatory T cells, as well as the
balance between the effector and regulatory arms of the
immune system, including conventional T cells, Th17,
and Th1 cells, between G-BM and G-PB.
Methods
G-CSF treatment of healthy donors and sample collection
G-BM and G-PB were obtained from 20 consecutive
allogeneic donors. As shown in Table 1, this group of
donors, 11 men and 9 women, provided informed con-
sent and had a median age of 29 years ranging from 18
to 54 years. Approval for this study was obtained from
the Institutional Review Board and Ethical Committee of
the Health Center at Peking University. Donors receivedrecombinant G-CSF (filgrastim; Kirin Co., Ltd., Tokyo,
Japan) at a dosage of 5 μg/kg/d for 5 consecutive days.
G-BM was collected on the 4th day of treatment by
aspiration, and G-PB was obtained on the 5th day by
leukapheresis using a continuous-flow blood cell separator
(Gambro BCT, Lakewood, CO, USA; or Baxter, Chicago,
IL, USA). The reason for using this protocol was that
patients in our institute receive transplants composed
of G-BM plus G-PB, which are harvested on days 4 and
5, respectively [20,21].
Immunophenotyping, intracellular staining and
multiparameter flow cytometric analysis
Samples were stained without further separation to
minimize selective losses shortly after collection. Combi-
nations of the directly conjugated monoclonal antibodies
CD3-V500, CD4-PerCP, CD56-PE, CD127-BV421, CD25-
PE-CY7, CD25-APC, CD62L-FITC, CD69-APC, CD45RA-
FITC, CCR7-PE, Ki67-FITC, Foxp3-APC (BD Bioscience,
Mountain View, CA, USA), CD16-APC/CY7, HLADR-
APC/CY7 (Biolegend, San Diego, CA, USA) and their
relative allotypes were used in individual 8-color flow
cytometry assays to analyze the immunophenotype of
regulatory T cells and effector T cells.
Intracellular staining was performed using the Intra-
cellular Staining Kit (eBioscience, San Diego, CA, USA).
The expression of Ki67 was determined in freshly isolated
CD4+CD25highFoxp3+ regulatory T cells. The cellular se-
cretion and function of cytokines were determined after
incubation of cells for 5 h with phorbol myristate acetate
(PMA) (100 ng/ml) plus ionomycin (2 ug/ml, all reagents
from Sigma Chemical Co., St. Louis, MO, USA) to stimu-
late maximal production of IL-17 and IFN-γ; GolgiStop
(0.7 μl/ml) was added to the samples during the last
4 hours to sequester the proteins in the cytoplasm [22,23].
Treg cell ex vivo suppression assay
We isolated human Treg (CD4+CD25+) and Tresp cells
(CD4+CD25−) from G-BM and G-PB using a human
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Biotec). Tresp cells were labeled with 5 μM 5,6-carboxy-
fluorescein diacetate succinimidyl ester (CFSE) (Biolegend).
A total of 1 × 104 CFSE-labeled Tresp cells were cultured
with unlabeled autologous Treg cells at different ratios,
including 1:1, 2:1, and 4:1, in round-bottom 96-well
plates in the presence of Treg Suppression Inspector
consisting of Anti-Biotin MACSiBead Particles that
were pre-loaded with biotinylated CD2, CD3, and
CD28 antibodies (Miltenyi Biotec). After 5 days, an
analysis of cell division was performed using the FACS-
Canto II system (BD Biosciences). The suppressive cap-
acity of Treg cells toward the cocultured responder cells is
expressed as the relative inhibition of the percentage of
CFSE low cells [100 × (1–% CFSE low Tresp cells in cocul-
ture/% CFSE low Tresp alone)].
Statistical analysis
To test the differences in the regulatory T cells and
effector T cells between donors treated with G-BM and
G-PB, a Wilcoxon signed-rank test or paired-sample T test
was used. P < 0.05 was considered statistically significant.
Results
Comparison of multiple regulatory T cells between G-BM
and G-PB
The cartoon in Additional file 1: Figure S1 addresses the
multiple alternative definitions of regulatory T cells and
provides a heuristic overview of how these various sub-
sets of T cells are related in ontogeny or in functional
capacities. The percentage of CD4+CD25highCD127-/dim
regulatory T cells and CD4+CD25−CD69+ regulatory T
cells among CD4+ T cells were significantly higher in G-
BM compared to G-PB (4.97% ± 2.72% vs. 3.16% ± 1.52%,
n = 20, p = 0.001; 6.27% ± 3.94% vs. 0.89% ± 0.92%, p <
0.001, Figure 1A, B and C). No statistically significant
differences were found between G-BM and G-PB in the
proportions of CD4+CD25highCD62L+ regulatory T cells
among CD4+ T cells (2.54% ± 2.23% vs. 3.41% ± 2.89%,
p = 0.204, Figure 1C and D). However, because of the
significantly higher numbers of CD4+ T cells in G-PB
compared to G-BM, the absolute numbers of CD4+
CD25highCD127-/low regulatory T cells, CD4+CD25high
CD62L+ regulatory T cells and CD4+CD25−CD69+
regulatory T cells were significantly lower in G-BM
than in G-PB (P < 0.0001, Figure 1E).
Considering that CD62L (L-selectin) is an important
T-cell homing receptor as well as a marker for T-cell
development and that CD69 is an important activating
receptor that exerts regulatory functions in the immune
response of T cells, we also compared differences in the
expression of CD62L and CD69 on CD4+CD25high
CD127-/low regulatory T cells between G-BM and G-PB.
Although the expression of CD62L was comparable inCD4+CD25highCD127-/low regulatory T cells (59.88% ±
25.07% vs. 54.96% ± 20.71%, Figure 1A), the expression
of CD69 was significantly higher in CD4+CD25high
CD127-/low regulatory T cells in G-BM compared with G-
PB (2.38% ± 2.21% vs. 0.78% ± 0.50%, p = 0.005, Figure 1A).
In addition, most of the CD4+CD25highCD62L+ regulatory
T cells were CD127 negative. The percentage of CD127
negative cells among CD4+CD25highCD62L+ regulatory T
cells was comparable between G-BM and G-PB (83.74% ±
13.69% vs. 85.33% ± 9.71%, p = 0.936). Therefore, the per-
centage of CD4+CD25highCD127-/dimCD62L+ regulatory T
cells was significantly higher in G-BM compared to G-PB
(3.43% ± 2.18% vs. 1.69% ± 1.54%, p = 0.006, Figure 1C).
A phenotypic analysis of the regulatory T cell compart-
ment revealed 3 distinct Treg populations (CD45RA+
HLADR−, CD45RA−HLADR+, CD45RA−HLADR−) in
G-BM and G-PB [24]. The percentage of CD45RA+
HLADR− naive Treg cells among the Treg cells was sig-
nificantly higher in G-BM compared to G-PB (29.26% ±
15.50% vs. 18.06% ± 10.85%, P = 0.009, Figure 2A-B).
However, the percentage of the CD45RA−HLADR+ Treg
subset (34.01% ± 9.17% vs. 37.61% ± 7.99%, P = 0.028)
and the CD45RA−HLADR−Treg subset (35.15% ± 8.98%
vs. 43.83% ± 7.20%, P = 0.004) was significantly lower in
G-BM compared to G-PB (Figure 2A-B). We also ob-
served that the expression of CCR7 in CD45RA+
HLADR− Treg cells was significantly higher than that in
CD45RA−HLADR+ Treg or in CD45RA−HLADR− Treg
cells (Figure 2C-D). The expression of CCR7 in Treg
cells overall was comparable in G-BM and G-PB. How-
ever, the percentage of CCR7-expressing CD45RA+
HLADR− naive Treg cells in G-BM was significantly
lower compared to those in G-PB (76.64% ± 6.23% vs.
84.02% ± 7.43%, P = 0.025, Figure 2C-D), but the MFI of
CCR7-expressing CD45RA+HLADR− naive Treg cells
was comparable (Figure 2E).
The expression of Ki67 in CD4+CD25highFoxp3+ Treg
cells was measured as a marker of cell proliferation. The
results from the entire cohort of patients and a repre-
sentative patient showed that CD4+CD25highFoxp3+
Treg cells in G-BM had higher levels of proliferation
than those in G-PB (50.93% ± 13.25% vs. 38.19% ± 8.95%,
P = 0.037, Figure 3).
Comparison of the in vitro suppression function of
regulatory T cells between G-BM and G-PB
To compare the suppressive activity of Treg cells between
G-BM and G-PB, we performed additional functional stud-
ies. The suppression assay was performed with a dilution
series ranging from a ratio of 1:1 to 4:1 of G-BM-Tresp
cells:G-BM-Treg cells or of G-PB-Tresp cells:G-PB-Treg
cells as outlined in Figure 4. As an additional control, G-
BM- or G-PB-Tresp were cultured alone with and without





Figure 1 Comparison of regulatory T cells between G-BM and G-PB. Panel A shows representative plots of CD4+CD25highCD127-/low regulatory T
cells as well as CD69 and CD62L expression on CD4+CD25highCD127-/low regulatory T cells. Panels B and D show the flow cytometry data for the
expression of CD4+CD25highCD62L+ regulatory T cells as well as CD4+CD25−CD69+ regulatory T cells in G-BM and G-PB gated on CD4+ T cells.
Panels C and E show a comparison of the percentage (%CD4+ T cells) and the absolute numbers (cells/μl) of the three types of regulatory T cells
mentioned above as well as CD4+CD25highCD127-/lowCD62L+ in G-BM and G-PB gated on CD4+ T cells (n = 20). *P < 0.05 by Wilcoxon signed-rank
test (median with interquartile range).
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Tresp cells in comparison to G-PB-Treg cells cocultured
with equal numbers of G-PB-Tresp cells. As shown for a
representative patient in Figure 4A-H, Treg cells suppressed
the proliferation of CFSE-labeled responder T cells from
the same donor, achieving the maximum suppression at a
1:1 ratio of Tresp to Treg cells. At a 1:1 ratio of Tresp to
Treg cells, no statistically significant differences were found
in the suppression capability of Treg cells among G-BM-
Treg cocultured with G-BM-Tresp (70.13% ± 15.12%), G-
BM-Treg cocultured with G-PB-Tresp (47.63% ± 14.73%),
or G-PB-Treg cocultured with G-PB-Tresp (51.36% ±
22.29%) (Figure 4I). Significant differences in the suppres-
sion rates were found at a G-BM Tresp:G-BM Treg ratiobetween 4:1 and 1:1 or 2:1 and 1:1 (P = 0.043 and P = 0.043,
respectively). Finally, a trend towards a higher suppression
rate at a G-BM Tresp:G-BM Treg ratio of 2:1 compared to
4:1 (P = 0.080) was observed (Figure 4I).
Comparison of the ratio of regulatory T cells and effector
T cells between G-BM and G-PB
We found no statistically significant differences comparing
G-BM and G-PB with respect to the proportions of CD4+
T cells with a conventional T cell phenotype (CD4+
CD25lowCD127+; 75.60% ± 5.41% vs. 73.99% ± 7.97%, P =
0.247, Figure 5A) and Th17 cells (3.86% ± 1.96% vs.
2.79% ± 1.40%, p = 0.126, Figure 5B). The proportions
of Th1 cells in CD4+ T cells were significantly higher in
Figure 2 Comparison of regulatory T cell subsets between G-BM and G-PB. Panels A and B show representative plots and a comparison of 3
distinct Treg populations (CD45RA+HLADR−, CD45RA−HLADR+, CD45RA−HLADR−) in G-BM and G-PB gated on CD4+CD25highCD127-/low regulatory
T cells (n = 5); Panels C, D and E show representative plots and a comparison of the differences in the percentage of CCR7 expression and MFI
among 3 Treg populations (n = 5). *P < 0.05 by Wilcoxon signed-rank test (median with interquartile range).
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± 9.09%, p < 0.001, Figure 5C). However, similar to the
differences in regulatory T cells between G-BM and G-
PB, the absolute numbers of conventional T cells, Th17
cells and Th1 cells were significantly lower in G-BM
than those in G-PB (P < 0.0001, Figure 5D).In addition to comparisons of individual subsets of T
cells between G-BM and G-PB, it is important to examine
the relative balance of the effector and regulatory arms of
the immune system. The ratio of CD4+CD25lowCD127+
conventional T cells to CD4+CD25highCD127-/low regula-
tory T cells was significantly lower in G-BM compared to
A B C
Figure 3 Comparison of the proliferation of regulatory T cell subsets between G-BM and G-PB. Panel A. Percentage of Ki67 expression on freshly
separated CD4+CD25highFoxp3+ Treg cells in G-BM and G-PB (n = 12). Panels B and C. Flow cytometry plots (the percentage of Ki67 Treg cells is








Figure 4 Comparison of the in vitro suppression function of regulatory T cell subsets between G-BM and G-PB. Panels A-D. Representative flow
cytometry plots of the proliferation of CFSE-labeled responder T cells in G-BM without (A) or with Treg Suppression Inspector (Miltenyi Biotec)
co-cultured without (B) or with an increasing number of Treg cells at ratios of 4:1 (C), 2:1(D), and 1:1(E) of Tregs in G-BM. Panels F-H. Proliferation
of CFSE-labeled responder T cells in G-PB with Treg Suppression Inspector (Miltenyi Biotec) co-cultured without (F) or with equal numbers of Treg
cells from G-PB (G) or G-BM (H). Panel I. Suppression functions of Treg cells in inhibiting T-cell activation. G-BM-Treg indicates Tregs from G-BM,
G-BM Tresp indicates Tresp from G-BM, G-PB-Treg indicates Tregs from G-PB, and G-PB Tresp indicates Tresp from G-PB (n = 5). *P < 0.05 by
Wilcoxon signed-rank test (mean ± SD).





Figure 5 Comparison of effector T cells between G-BM and G-PB. Panels A-C show the percentage of CD25low/-CD127+ expression (A, Conventional T
cells, Tcon), IL17 secretion (B, Th17 cells), and IFN-γ secretion (C, Th1 cells) on freshly separated CD4+ cells in G-BM and G-PB (n = 20). Panel D shows
the comparison of the absolute numbers (cells/μl) of Tcon, Th17, and Th1 cells between G-BM and G-PB (n = 20). Panel E shows the ratio of Tcon cells
to CD4+CD25highCD127-/Low Treg cells in G-BM and G-PB (n = 20). *P≤ 0.05 by Wilcoxon signed-rank test (median with interquartile range).
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Figure 5E). In addition, the ratio of CD4+CD25lowCD127+
conventional T cells to CD4+CD25highCD127-/lowCD62L+
regulatory T cells was also lower in G-BM compared to
that in G-PB (35.28 ± 29.11 vs. 78.02 ± 57.02, P = 0.008).
The ratios of Th17 cells to CD4+CD25highCD127-/low
regulatory T cells were comparable between G-BM and
G-PB (P = 0.970).
Correlations of regulatory T cells between G-BM and G-PB
Positive correlations were found between the propor-
tions of CD4+CD25highCD127-/low regulatory T cells
and CD4+CD25highCD62L+ regulatory T cells in G-BM
(R = 0.758, P < 0.001, Figure 6A) and in G-PB (R =
0.871, P < 0.001, Figure 6B), but not for CD4+CD25−CD69+ regulatory T cells in G-BM (R = 0.385, P = 0.094)
and in G-PB (R = 0.134, P = 0.575).
Finally, positive correlations were found between G-BM
and G-PB in the proportions of CD4+CD25highCD127-/low
regulatory T cells (R = 0.625, P = 0.003, Figure 6C), the
proportions of CD4+CD25highCD62L+ regulatory T cells
(R = 0.518, P = 0.019, Figure 6D), and the proportions of
CD4+CD25−CD69+ regulatory T cells (R = 0.508, P = 0.022,
Figure 6E).
Discussion
This is the first study to explore the differences between
G-BM and G-PB with regard to the Treg cell contents as
well as the balance between effector T cells and regula-





Figure 6 Correlations of CD4+CD25highCD127-/low and CD4+CD25highCD62L+ regulatory T cells. Panels A-B. Correlations of CD4+CD25highCD127-/low and
CD4+CD25highCD62L+ regulatory T cells in G-BM (A) and G-PB (B). Panels C-D. Correlations of CD4+CD25highCD127-/low (C) and CD4+CD25highCD62L+
regulatory T cells (D) and CD4+CD25−CD69+ regulatory T cells (E) between G-BM and G-PB.
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however, the proportions of regulatory T cells and Th1
cells were significantly higher in G-BM compared to
G-PB. Therefore, although the absolute number of
regulatory T cells, conventional T cells, Th17 cells, or
Th1 cells were significantly lower in G-BM compared
to G-PB, the ratio of conventional T cells to CD4+
CD25highCD127-/low Treg cells was significantly lower
in G-BM compared to G-PB, which could partially
contribute to the lower incidence of acute GVHD in
G-BM transplantation compared to G-PB transplantation.
The CD4+CD25highCD127-/low Treg subsets could me-
diate peripheral T-cell homeostasis and contribute to
self-tolerance [25]. Not only the frequencies of CD4+
CD25highCD127-/low Treg cells but also those of CD4+CD25highCD127-/lowCD62L+ Treg cells were significantly
higher in G-BM compared to G-PB. In addition, the
fraction of proliferating CD4+CD25highFoxp3+ T cells
was significantly higher in G-BM than in G-PB, which
might contribute to the higher frequencies of regulatory
T cells in G-BM compared to G-PB. Zou WP and col-
leagues demonstrated that the bone marrow is a reser-
voir for CD4+CD25+ regulatory T cells that traffic by
means of CXCL12/CXCR4 signaling. G-CSF reduces the
expression of human bone marrow CXCL12 in vivo,
which is associated with the mobilization of bone marrow
Treg cells to the peripheral blood in human volunteers
[17]. Boyer O and colleagues found that the frequencies of
Treg cells were still significantly lower in G-PB compared
to BM transplants. In addition, G-CSF administration and
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CD62L+ Treg cell subset [16]. Consistent with Boyer O
et al., our data demonstrated that the expression of
CD62L on CD4+CD25highCD127-/low Treg cells was com-
parable in G-PB or in G-BM, confirming that G-CSF
administration contributes to the loss of CD62L on Treg
cells. In addition, the lower levels of CCR7 in CD45RA+
HLADR− Treg cells in G-BM also indicate a regulatory
influence of G-CSF on human Treg-cell migration and
suggests a role in the redistribution of Treg cell subsets
to the peripheral blood, involving CD62L, CCR7, and
CXCL12/CXCR4 signals. It has been suggested that
CD62L+ Treg cells may have higher immunosuppressive
properties in vitro than CD62L− Treg cells [10] and possess
the capacity to control GVHD [11,26]. CD69 deficiency
leads to diminished levels of TGF-β that contribute to
an enhanced immune response, resulting in increased
inflammation in a collagen-induced arthritis model
[12,27]. Therefore, our data suggested that the higher
frequencies of CD4+CD25highCD127-/lowCD62L+ Treg
cells as well as the higher expression of CD69 on Treg
cells in G-BM would help maintain the hyporespon-
siveness of G-BM compared to G-PB. In addition, dis-
tinct human Treg subsets have been described by
analyzing cell-surface markers, such as CD45RA and
HLADR. Of these, only the CD45RA+ naive cells within
the CD4 + CD25high T-cell compartment were involved,
as only this subpopulation homogeneously expressed
CD62L, CCR7, cytotoxic T lymphocyte–associated
antigen-4 (CTLA-4), and FOXP3, produced no inflam-
matory cytokines and maintained robust suppressive
activity after expansion [28]. The Treg compartment in
patients developing acute GVHD also showed a marked
depletion of CD45RA+HLADR−“naive” Treg cells com-
pared with tolerant patients [24]. Therefore, the higher
percentage of “naive” Treg cells in G-BM compared to
those in G-PB might indicate higher immunosuppressive
properties. However, the results of the in vitro Treg cell
suppression assay were comparable between G-BM and
G-PB. The limited number of samples studied and the se-
lection of CD4+ CD25+ Tregs using the Regulatory T cell
Isolation kit (Miltenyi Biotec) rather than fluorescence-
activated cell sorting might affect the cell suppressive
activities reported herein. In addition, an imbalance in
the effector and regulatory CD4 T cells is associated
with GVHD after HSCT using a reduced intensity con-
ditioning regimen and alemtuzumab [29]. The high fre-
quency of CD4+CD25−CD69+ T cells is correlated with
a low risk of acute GVHD in allotransplants [8]. Thus,
the higher ratio of Tregs to conventional T cells as well
as higher frequencies of CD4+CD25−CD69+ T cells in
G-BM compared to G-PB would support the lower oc-
currence of acute GVHD post-G-BM transplantation
compared to G-PB transplantation [2].Correlations were found in CD4+CD25highCD127-/low
Treg cells and CD4+CD25highCD62L+ Treg cells but not
in CD4+CD25−CD69+ T cells between G-BM and G-PB,
suggesting that the CD4+CD25highCD127-/low Treg cells
and CD4+CD25highCD62L+ Treg cells in G-PB might de-
rive from BM and might overlap each other; however,
the development of CD4+CD25−CD69+ T cells in G-PB
had no direct relevance to those in G-BM, which will
need to be confirmed in the future.
Although acute GVHD has been classically assumed to
be Th1-mediated on the basis of findings in animal
models, we now face a more complex scenario involving
possible roles of newly identified Th17 cells as well as
Treg cells in GVHD [30]. The differential expression of
chemokine receptors and selectin ligands on each Th
subset may ensure the unique ability of each Th subset
to induce tissue-specific GVHD [31], and the absence of
regulatory T-cell control of Th1 and Th17 cells is re-
sponsible for the autoimmune-mediated pathology in
chronic graft-versus-host disease [32]. Thus, it appears
that a delicate balance among Th1, Th2, Th17, and Treg
cells after transplantation is an important determinant of
the severity, manifestation, and tissue distribution of
GVHD. In this study, the ratio of Th17 cells and Treg
cells were comparable between G-BM and G-PB, but the
percentages of Th1 in G-BM were higher compared with
G-PB. It is not clear whether the Th1 cells could con-
tribute to the prevention or initiation of GVHD post-
transplantation [33,34]. Yi et al. have demonstrated that
the absence of Th17 cells leads to augmented Th1 differ-
entiation and exacerbated acute GVHD [31]. Waller
et al. showed that donor bone marrow precursors of
plasmacytoid dendritic cells (pre-pDCs) can activate
donor T cells toward Th1 immune polarization, then in-
duce indoleamine 2,3-dioxygenase synthesis to limit
GVHD by altering the balance between donor Treg and
inflammatory T cells [33]. A better understanding of the
dynamic process of reciprocal differentiation of Th and
regulatory cell subsets as well as their complex interac-
tions would help establish novel graft engineering that
modulates the fine balance between Th and Treg subsets
to improve the outcome of allo-HSCT.
Conclusions
In summary, this study demonstrated that higher frequen-
cies of regulatory T cells and a decreased ratio of effector
T cells to regulatory T cells in G-BM would lay part of the
immunological groundwork for a lower occurrence of
acute or chronic GVHD post-G-BM transplantation com-
pared to G-PB transplantation. Conducting a large cohort
study in a prospective manner would be warranted to
compare the different clinical outcomes between G-BM
and G-PB transplants and their correlation with different
Th and Treg subsets within G-BM or G-PB allografts.
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relationships among different regulatory T cells. A common ontogenic
pathway might exist between the CD4+CD25highCD62L+ regulatory T cells
and CD4+CD25highCD127-/low regulatory T cells. Both CD4+CD25highCD62L+
regulatory T cells and CD4+CD25highCD127-/low regulatory T cells can originate
from the thymus or mature CD4+CD25high T lymphocytes, and there may be
overlap between these two regulatory T cells populations. A phenotypic
analysis of the CD4+CD25highCD127-/low regulatory T cell compartment
revealed 3 distinct populations (CD45RA+HLADR−, CD45RA−HLADR+, CD45RA−
HLADR−). CD4+CD25−CD69+ T cells are generated from mature CD4+CD25−
T lymphocytes after TGF-β induction. CD69 can be persistently expressed by
these cells without CD25 expression. All of these three regulatory T cells
populations can inhibit effector T cell function to reduce inflammation and
therefore play immunoregulatory roles.
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